Journal of the American Heart Association

APRIL 16, 2025

BackgroundAortic stenosis can lead to cardiac adaptations and symptoms similar to heart failure with preserved ejection fraction. Journal of the American Heart Association, Ahead of Print. Methods and ResultsThis retrospective cohort study included 469 patients with moderate aortic stenosis.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Aortic valve Aortic Heart Failure 45

HeartRhythm

SEPTEMBER 25, 2024

The HFA–PEFF score comprising echocardiographic and laboratory data is designed to diagnose heart failure with preserved ejection fraction and holds prognostic value in patients who underwent catheter ablation for atrial fibrillation (AF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Laboratory Atrial Fibrillation Ablation 40

HeartRhythm

APRIL 30, 2024

Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

MAY 22, 2024

The combined effect of left ventricular ejection fraction (LVEF) and atrial fibrillation (AF) on clinical outcomes in heart failure (HF) remains complex.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Outcomes 40

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

HeartRhythm

APRIL 30, 2024

The combined effect of Left Ventricular Ejection Fraction (LVEF) and the presence of Atrial Fibrillation (AF) on clinical outcomes in heart failure (HF) patients remains complex.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Outcomes 40

HeartRhythm

APRIL 30, 2024

A number of studies have examined the impact of atrial fibrillation (AF) ablation on outcomes in heart failure (HF) with reduced ejection (HFrEF) patients. In contrast, data from HF with preserved ejection fraction (HFpEF) patients is limited to small outcome studies and less robust meta-analyses.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 13, 2024

Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.

Atrial Fibrillation 40

Atrial Fibrillation Preserved Ejection Fraction Heart Failure Hospital 40

HeartRhythm

APRIL 30, 2024

Overtime, various studies have reported variable mortality outcomes in heart failure with preserved ejection fraction (HFpEF) patients. It remains unclear to what extent atrial fibrillation (AF) creates increased mortality alone or in combination with either HFpEF or heart failure with reduced ejection fraction (HFrEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Outcomes 40

HeartRhythm

APRIL 30, 2024

Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

OCTOBER 18, 2024

The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains unclear.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Ablation Atrial Fibrillation Heart Failure 45

DAIC

FEBRUARY 29, 2024

This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center. The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

European Journal of Heart Failure

APRIL 13, 2025

The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. The primary outcome was the composite of cardiovascular death and total worsening HF events.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Pulmonary Peripheral Arterial Disease 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Journal of Cardiovascular Electrophysiology

OCTOBER 21, 2024

Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). However, the long-term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Beta-blocker use and outcomes in patients with HFmrEF/HFpEF. Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Outcomes were generally consistent across the patient subgroups examined.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Atrial Fibrillation 40

European Journal of Heart Failure

NOVEMBER 3, 2024

Abstract Aims Atrial fibrillation (AF) is common in heart failure (HF) and negatively impacts outcomes. The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

DECEMBER 19, 2024

BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Outpatient 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

DECEMBER 7, 2023

ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). Further study is required to define optimal strategies to treat and prevent biatrial myopathy in HFpEF. This article is protected by copyright.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Atrial Fibrillation 40

Open Heart

JANUARY 18, 2024

Background The Heart Failure Association Pretest assessment, echocardiography and natriuretic peptide, functional testing and final aetiology (HFA-PEFF) score has been developed for diagnosing heart failure with preserved ejection fraction (HFpEF), which is frequently associated with atrial fibrillation (AF).

Atrial Fibrillation 52

Atrial Fibrillation Preserved Ejection Fraction Ablation Outcomes 52

Circulation: Heart Failure

OCTOBER 27, 2023

The primary outcome of each was the composite of worsening heart failure or cardiovascular death.Results:Among patients with SR (n=6401, 64%), the rate of the primary outcome was higher in those with higher HR: 16.8 HR was not associated with outcomes in patients in AF for either heart failure phenotype.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Outcomes 40

Open Heart

FEBRUARY 15, 2023

Aims Atrial functional mitral regurgitation (AFMR) is characterised by left atrial and consequent mitral annular dilatation causing mitral regurgitation. Here, we aim to define the prevalence and characterise the patient and survival characteristics of AFMR in the National Echocardiographic Database of Australia (NEDA).

Bicuspid/Mitral 52

Bicuspid/Mitral Preserved Ejection Fraction Pulmonary Atrial Fibrillation 52

DAIC

JUNE 26, 2024

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Frontiers in Cardiovascular Medicine

NOVEMBER 10, 2024

BackgroundHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coincide. g/m2, P = 0.027), reduced distance in the 6-min-walk-test (median: 453 m vs. 527 m, P = 0.008) and higher left atrial pressures (median: 14.0 mmHg ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2,

Preserved Ejection Fraction 52

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 52

Open Heart

DECEMBER 3, 2024

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on its prevalence, severity and prognostic implications have not been well defined. Adjusted risk (HR) of mortality increased 1.28-fold fold (95% CI 1.15 to 1.41), 1.51-fold fold (95% CI 1.38 to 1.65) and 3.47-fold

Pulmonary 52

Pulmonary Preserved Ejection Fraction Hypertension Atrial Fibrillation 52